COVID-19 Update: UH has Multiple Sclerosis Research
Our team is involved in several research projects in MS and other neuroimmunological disorders including observational studies, clinical trials, immunological studies, neurophysiological studies, and neuro-rehab research, among others.
- Exchange trial for patients with multiple sclerosis
-
We are currently enrolling in the EXCHANGE trial (Exploring the safety and tolerability of conversion to dose-titrated Oral Siponimod in patients with advancing forms of relapsing multiple sclerosis: A 6-month open label, multi-center Phase IIIb study).
This is a trial for patients with multiple sclerosis. The study is looking at how well patients tolerate changing medication for multiple sclerosis from their current medication to an investigational drug called siponimod. The information learned in the study will help doctors understand if and when they should switch patients from their current MS medications to siponimod, as well as how safe and tolerable this is for patients.
You may qualify if:
- You are 18-65 years old
- You have advancing RMS (relapsing multiple sclerosis)
- You have been continuously treated with beta-interferons, glatiramer acetate, fingolimod, dimethyl fumarate, or teriflunomide for at least 3 months at the time of consent
* The study staff will review your medications with you to determine if you are eligible if you are interested in participating.
- VERISMO trial for patients with multiple sclerosis
-
We are currently enrolling in the VERISMO trial (AN OBSERVATIONAL STUDY OF OCRELIZUMAB TREATED PATIENTS WITH MULTIPLE SCLEROSIS TO DETERMINE THE INCIDENCE AND MORTALITY RATES OF BREAST CANCER AND ALL MALIGNANCIES (VERISMO STUDY) for patients with multiple sclerosis. The purpose of the VERISMO Study is to learn more about the long-term effect of ocrelizumab, which may help doctors better know how to use this medication in the future Your participation will last for at least 5 years. During this time, information will be collected from your medical records. No particular activities will be required of you, other than keeping your doctor informed about any changes to your health and medications. Being in this study will not affect how your MS is treated or how often you visit the clinic.
You may be able to take part if you:
- are 18 years of age or older
- have been diagnosed with MS
- are starting or just started treatment with ocrelizumab or another treatment for MS (first dose maximally 30 days before entering the study)
- have not used rituximab in the past